Starling Oncology (STLN) Q2 2026: Capitated Revenue Growth Accelerates with $50 Million New Contracts Outside Florida
Starling Oncology demonstrated robust expansion in its capitated revenue streams highlighted by the addition of three new delegated contracts outside its Florida base, signaling a strategic geographic diversification. Operational efficiencies and improved medical loss ratio (MLR) management supported the company’s second consecutive profitable quarter, underpinning confidence in scaling its value-based oncology care model. The company raised its full-year revenue and profitability guidance, reflecting strong momentum and a strengthened balance sheet following a key refinancing.
Summary
- Geographic Expansion Solidifies National Footprint: New delegated capitation contracts in Nevada and Oregon mark Starling’s first capitated growth outside Florida.
- Operational Leverage Evident: Improved gross margins and disciplined SG&A spending underpin positive adjusted EBITDA and cash flow generation.
- Data-Driven Provider Integration: The upcoming Starling Nexus portal aims to enhance clinical pathway adherence and ancillary service utilization.
Business Overview
Starling Oncology is a value-based oncology care provider operating through capitated and fee-for-service arrangements, delivering integrated cancer treatment and specialty pharmacy services. Its revenue is primarily generated from capitated contracts, where the company receives fixed payments per member (capitated lives) to manage oncology care, and from specialty pharmacy prescription volumes. The business is segmented into Patient Services, including capitated contracts, and Specialty Pharmacy, which comprises the majority of revenue.
Performance Analysis
Starling Oncology reported second quarter 2026 revenue of $161.3 million, up 34.6% year-over-year, driven by 57.6% growth in Specialty Pharmacy revenue and 5.3% growth in Patient Services revenue. Specialty Pharmacy now represents 61.1% of total revenue, reflecting strong prescription fill volume growth and operational scale. Gross profit improved by 55% year-over-year to $27.2 million, with overall gross margin expanding 225 basis points to 16.8%, supported by procurement optimizations and clinical pathway management.
Despite gross profit growth, Patient Services gross profit declined 57%, primarily due to increased clinical labor staffing ahead of new contract launches, conservative fee-for-service approaches, and natural MLR increases as new lives are onboarded. The company disclosed an 85.5% MLR for the quarter, reflecting medical costs relative to capitated revenue, and expects this to fluctuate between 80% and 90% over the next year. Operating leverage is evident as SG&A expenses decreased as a percentage of revenue by approximately 390 basis points to 18.6%, enabling adjusted EBITDA of $0.2 million, a notable improvement from a loss of $4.1 million a year ago.
- Capitated Revenue Diversification: Addition of three delegated capitation contracts outside Florida adds 80,000 lives and $50 million annualized revenue.
- Margin Expansion in Specialty Pharmacy: Gross margin improved to 21.6% driven by scale and procurement initiatives, partially offsetting Patient Services margin pressure.
- Cash Flow Improvement: Operating cash flow turned positive at $9.7 million for the first half of 2026, reflecting EBITDA gains and working capital management.
The quarter’s financial results underscore Starling’s progress in scaling its capitated model nationally while maintaining cost discipline and improving profitability metrics.
Executive Commentary
"We are reporting a very strong second quarter with profitability and completion of a strategic refinancing. The business is continuing to track increasing profitability quarter over quarter in 2026. Our capitated contract growth remains robust, and our Part D business is continuing to set monthly fill records."
Dan Virnich, Chief Executive Officer
"We completed a strategic refinancing that extends our debt maturities to 2031, improves liquidity and operating flexibility, and gives us committed funding as we continue to scale the business. Our adjusted EBITDA improved by approximately $4.3 million year-over-year, reflecting growth in specialty pharmacy and ongoing cost discipline."
Rob Carter, Chief Financial Officer
Strategic Positioning
1. Geographic Expansion Beyond Florida
Starling Oncology’s addition of three new delegated capitation contracts in Nevada, Oregon, and expanded exclusivity in California marks a key strategic pivot from its Florida-centric base. The 80,000 new capitated lives outside Florida, representing approximately $50 million in annualized revenue, diversify risk and open new growth markets. The California exclusivity deal adds 230,000 Medi-Cal lives, leveraging Starling’s network and care coordination strengths despite lower capitation rates due to younger demographics.
2. Enhanced Provider Integration via Starling Nexus Portal
The launch of Starling Nexus in mid-August aims to standardize clinical order submission and pre-authorization processes across employed and networked physicians. This technology platform is expected to drive adherence to clinical care pathways, improve utilization management, and facilitate ancillary services like Part D pharmacy and decentralized clinical trials. The portal will also generate rich data insights into practice patterns, supporting ongoing MLR management and quality improvement.
3. Improving Profitability through Operational Efficiency
Operational leverage is evident as SG&A expenses declined as a percentage of revenue despite investments in staffing ahead of contract launches. Procurement initiatives in the specialty pharmacy segment have driven gross margin expansion above 21%, partially offsetting margin pressure in Patient Services due to increased clinical labor and onboarding new lives. The company’s strategic refinancing improved liquidity without equity dilution, supporting continued investment and scaling.
4. Transparent Medical Loss Ratio Reporting
Starling introduced MLR disclosure for capitated members to provide greater transparency into medical cost trends. The elevated 85.5% MLR reflects onboarding dynamics and is expected to stabilize between 80% and 90%. This metric offers investors a clearer view of the capitated model’s health and cost management effectiveness as the company scales.
5. Capital Structure Strengthening to Support Growth
The July refinancing replaced an $86 million convertible note with a $75 million term loan, extending debt maturities to 2031 and improving financial flexibility. This move reduces near-term refinancing risk and supports Starling’s aggressive capitation growth plans, including an expected doubling of capitated revenue in 2027.
Key Considerations
Starling Oncology’s Q2 results reflect a company transitioning from regional to national scale, balancing growth with margin management and operational discipline. The following points are critical for investors to monitor:
- Capitated Contract Ramp Timing: Delays in the Florida statewide contract push some revenue and EBITDA contribution from Q3 to Q4, though overall 2026 guidance was raised due to new wins.
- MLR Variability: Elevated MLR during onboarding of new capitated lives signals short-term cost pressure, but management expects stabilization as care coordination matures.
- Specialty Pharmacy Margin Sustainability: Procurement-driven margin gains may moderate but remain above historical levels, supporting overall profitability.
- Brand Transition Risks: The recent rebranding to Starling Oncology carries execution risk in partner and patient recognition, though management has initiated targeted communication campaigns.
- Provider Portal Adoption: The success of Starling Nexus in driving clinical pathway adherence and ancillary revenue growth will be a key operational catalyst to watch.
Risks
Starling faces risks related to the timing of capitated contract implementations, particularly the delayed Florida statewide launch, which could impact near-term revenue and profitability. The company’s elevated MLR during rapid member onboarding may pressure margins if medical cost trends worsen. Additionally, competitive dynamics in oncology value-based care and execution risks related to the new provider portal and brand transition could affect growth momentum.
Forward Outlook
For Q3 2026, Starling expects adjusted EBITDA to be positive but modest, in the range of $0.5 million to $1.5 million, reflecting the onboarding of 230,000 new members and associated ramp costs. Full-year 2026 guidance was raised to revenue between $650 million and $670 million, gross profit of $105 million to $110 million, adjusted EBITDA of $2 million to $7 million, and free cash flow between $5 million and $15 million. Management highlighted ongoing specialty pharmacy strength and a robust pipeline of capitated contracts as drivers of this outlook.
Takeaways
Starling Oncology’s Q2 results demonstrate the company’s successful shift toward a scalable, national value-based oncology platform. The combination of strong specialty pharmacy growth, expanding capitated contracts beyond Florida, and operational efficiencies underpin improved profitability and cash flow. The launch of the Starling Nexus portal signals a strategic emphasis on technology-enabled care coordination and data-driven management. Investors should monitor the company’s ability to manage MLR variability, execute on new contract ramps, and sustain specialty pharmacy margins as key indicators of future performance.
- Capitated Expansion Drives Growth: The addition of 310,000 capitated lives across new states materially diversifies Starling’s revenue base and enhances its competitive position in value-based oncology care.
- Operational Leverage Supports Profitability: Margin improvements in specialty pharmacy and disciplined SG&A management have enabled the company to reach adjusted EBITDA profitability for the second consecutive quarter.
- Technology Integration Is a Strategic Catalyst: The upcoming provider portal launch is poised to enhance clinical adherence and ancillary revenue, representing a critical execution focus for the company’s next growth phase.
Conclusion
Starling Oncology’s second quarter 2026 results reflect a company advancing its strategic transformation into a national value-based oncology leader. The significant growth in capitated contracts outside Florida, improved profitability metrics, and strengthened balance sheet position the company well for accelerated growth in 2027. Execution on provider integration and managing medical cost trends will be pivotal to sustaining momentum.
Industry Read-Through
Starling’s expansion into new states and increasing capitated lives underscore the growing industry trend toward value-based oncology care, where payers seek integrated, cost-effective cancer management solutions. The company’s transparent MLR reporting and provider portal rollout highlight the increasing importance of data-driven care coordination in improving outcomes and controlling costs. Other oncology care providers and payers should watch Starling’s approach to geographic diversification and technology integration as a model for scaling value-based care nationally.